يعرض 1 - 10 نتائج من 62 نتيجة بحث عن '"Glen Clack"', وقت الاستعلام: 1.54s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    المؤلفون: R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

    المصدر: Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)

    مصطلحات موضوعية: Science

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2041-1723Test

    الوصول الحر: https://doaj.org/article/b14be29b81754bafad04d4aa37714251Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    المؤلفون: R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

    المصدر: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

    مصطلحات موضوعية: Science

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2041-1723Test

    الوصول الحر: https://doaj.org/article/4ff05e79a58f49b980db63215fe0a4b3Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  3. 3
    Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

    المؤلفون: Sacha J Howell, Laura M Kenny, Simon Lord, Matthew G Krebs, Tobias Arkenau, Richard Baird, Iain R MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Anthony GM Barrett, Paul A Dickinson, Matthew J Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh, Charles Coombes

    المصدر: Cancer Research. 82:P1-18

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::88c35ef063a0d082b50ac42bfae220a1Test
    https://doi.org/10.1158/1538-7445.sabcs21-p1-18-10Test


    أضف إلى المفضلة
  4. 4
    Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

    المؤلفون: Charles Coombes, Sasha J Howell, Matthew G Krebs, Simon Lord, Laura M Kenny, Ash Bahl, Glen Clack, Edward Ainscow, Paul A Dickinson, Raluca Fostea, Janine Mansi, Carlo Palmieri, Gianflippo Bertelli, Rinath Jeselsohn, Zahi Mitri, William J Gradishar, Sagar Sardesai, Joyce O'Shaughnessy, Patrick Ward, Pavani Chalasani, Manfred Lehnert, Simak Ali, Stuart McIntosh

    المصدر: Cancer Research. 82:GS3-10

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ab14751d8b635b13c2effbd7bdbdb5c6Test
    https://doi.org/10.1158/1538-7445.sabcs21-gs3-10Test


    أضف إلى المفضلة
  5. 5
    Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials : using real clinical data and simulation studies

    المؤلفون: J Marshall, Glen Clack, J Young, Stefan Symeonides, Gareth James

    المصدر: BMC Cancer
    BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
    James, G D, Symeonides, S N, Marshall, J, Young, J & Clack, G 2021, ' Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies ', BMC Cancer . https://doi.org/10.1186/s12885-020-07703-6Test

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Maximum Tolerated Dose, Bayesian probability, Phase 1, Bayesian, lcsh:RC254-282, 01 natural sciences, Continual reassessment method, 010104 statistics & probability, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Dose escalation, Humans, Computer Simulation, 0101 mathematics, Skeleton, Mathematics, Dose limiting toxicity, Clinical Trials, Phase I as Topic, Dose-Response Relationship, Drug, Models, Theoretical, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Skeleton (computer programming), Confidence interval, Clinical trial, Research Design, 030220 oncology & carcinogenesis, Maximum tolerated dose, Research Article

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a3d872a242a38202d4342999950160Test
    https://eprints.whiterose.ac.uk/169936/1/James2021_Article_AssessmentOfVariousContinualRe.pdfTest


    أضف إلى المفضلة
  6. 6
    Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

    المؤلفون: Vinod Ravi, Michael Wagner, Tom Wei-Wu Chen, Herbert H Loong, Robert Mennel, Cheuh-Chuan Yen, Glen Clack, David Cutler, Rudolf Kwan, Wing=Kai CHan

    المصدر: Cancer Research. 81:PS13-05

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Taxane, business.industry, Phases of clinical research, Neutropenia, medicine.disease, Gastroenterology, Breast cancer, Oncology, Tolerability, Internal medicine, medicine, Angiosarcoma, Progression-free survival, business, Progressive disease

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bd5b0129daabf9de5298ad3d4f01896cTest
    https://doi.org/10.1158/1538-7445.sabcs20-ps13-05Test


    أضف إلى المفضلة
  7. 7
    Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

    المؤلفون: Brunella Felicetti, Paul Frewer, Juanita Lopez, Anthony El-Khouiery, Glen Clack, Christine Stephens, Simon J. Hollingsworth, Matthew G Krebs, Alan Lau, Andrew Goldwin, Alienor Berges, Jean-Charles Soria, Gemma N Jones, Sophie Postel-Vinay, Itziar Irurzun-Arana, Emma Dean, Sy Amy Cheung, Timothy A. Yap, Andrew J. Pierce, Simon Smith

    المصدر: Yap, T, Krebs, M, Postel-Vinay, S, El-Khouiery, A, Soria, J-C, Lopez, J, Berges, A, Cheung, S Y A, Irurzan-Arana, I, Goldwin, A, Felicetti, B, Jones, G, Lau, A, Frewer, P, Pierce, A, Clack, G, Stephens, C, Smith, S, Dean, E J & Hollingsworth, S J 2021, ' Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-1032Test

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Indoles, Neutropenia, Maximum Tolerated Dose, Anemia, Morpholines, Ataxia Telangiectasia Mutated Proteins, Gastroenterology, Carboplatin, chemistry.chemical_compound, Pharmacokinetics, Internal medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Sulfonamides, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Nuclear Proteins, Common Terminology Criteria for Adverse Events, medicine.disease, Thrombocytopenia, Pyrimidines, Oncology, Tolerability, chemistry, Pharmacodynamics, Sulfoxides, business

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5158d7388a6bd09605d2ca9977160f12Test
    https://pubmed.ncbi.nlm.nih.gov/34301752Test


    أضف إلى المفضلة
  8. 8
    265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

    المؤلفون: Sahirzeeshan Ali, E. Ainscow, Ash Bahl, Sagar Sardesai, Janine Mansi, H-T. Arkenau, M. Lehnert, P. Richards, Simon Lord, S. McIntosh, Glen Clack, R. C. Coombes, Sacha J Howell, Laura M. Kenny, Z. Mitri, Rinath Jeselsohn, Joyce O'Shaughnessy, Matthew G Krebs, Carlo Palmieri, William J. Gradishar

    المصدر: Annals of Oncology. 32:S477-S478

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Fulvestrant, business.industry, HER2 negative, Hematology, medicine.disease, Breast cancer, Hormone receptor, Internal medicine, medicine, In patient, Cyclin-dependent kinase 7, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::08b6b9a5d594a26b1180a26321d43ebdTest
    https://doi.org/10.1016/j.annonc.2021.08.548Test


    أضف إلى المفضلة
  9. 9
    PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

    المؤلفون: Martin Forster, Kabir Mohammed, Glen Clack, Clare Peckitt, Simon Smith, Kevin J. Harrington, James Spicer, Udai Banerji, Magnus T. Dillon, J. Guevara, Mark P Saunders, Z. Boylan, D. Smith

    المصدر: Clinical and Translational Radiation Oncology
    Clinical and Translational Radiation Oncology, Vol 12, Iss, Pp 16-20 (2018)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Drug, medicine.medical_specialty, Palliative Radiation Therapy, media_common.quotation_subject, medicine.medical_treatment, R895-920, DNA damage response, ATR inhibition, Article, Medical physics. Medical radiology. Nuclear medicine, 03 medical and health sciences, Phase I, 0302 clinical medicine, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Single agent, RC254-282, Radiosensitization, media_common, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Phase i study, Clinical trial, Radiation therapy, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, business, Ataxia telangiectasia and Rad3 related

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af72664b1a4b0ae26730f52c142e0f0Test
    https://doi.org/10.1016/j.ctro.2018.06.001Test


    أضف إلى المفضلة
  10. 10
    230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

    المؤلفون: Ash Bahl, Iain R. Macpherson, M. Lehnert, M. J. Fuchter, Glen Clack, Matthew G Krebs, Simon Lord, Agm Barrett, R. C. Coombes, S. McIntosh, Sahirzeeshan Ali, E. Ainscow, Paul A. Dickinson, Richard D. Baird, Laura M. Kenny

    المصدر: Annals of Oncology. 32:S458

    مصطلحات موضوعية: Oncology, Class (computer programming), medicine.medical_specialty, business.industry, Internal medicine, Medicine, In patient, Hematology, First in human, Modular design, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2924f5e469629675cda04bff64bf1a73Test
    https://doi.org/10.1016/j.annonc.2021.08.513Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث